In this video, Motley Fool health-care analyst David Williamson looks at the newest hepatitis C partnership, this time between small biotech Idenix and big pharma Johnson & Johnson. The race is on to create a cure using a combination of the next generation of interferon-free drugs, and the companies without all the parts for a viable cocktail are frantically teaming up to gain traction before it is too late. Watch to find out what this newest collaboration means for investors in both companies.


David Williamson has no position in any stocks mentioned. Follow him on Twitter: @MotleyDavid

The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.